Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning

Neuroprotection against cerebral ischemia can be realized if the brain is preconditioned by previous exposure to a brief period of sublethal ischemia. The present study was undertaken to test the hypothesis that nitric oxide (NO) produced from the neuronal isoform of NO synthase (NOS) serves as a ne...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cerebral blood flow and metabolism 1999-03, Vol.19 (3), p.331-340
Hauptverfasser: Gidday, Jeffrey M., Shah, Aarti R., Maceren, Raymond G., Wang, Qiong, Pelligrino, Dale A., Holtzman, David M., Park, T. S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 340
container_issue 3
container_start_page 331
container_title Journal of cerebral blood flow and metabolism
container_volume 19
creator Gidday, Jeffrey M.
Shah, Aarti R.
Maceren, Raymond G.
Wang, Qiong
Pelligrino, Dale A.
Holtzman, David M.
Park, T. S.
description Neuroprotection against cerebral ischemia can be realized if the brain is preconditioned by previous exposure to a brief period of sublethal ischemia. The present study was undertaken to test the hypothesis that nitric oxide (NO) produced from the neuronal isoform of NO synthase (NOS) serves as a necessary signal for establishing an ischemia-tolerant state in brain. A newborn rat model of hypoxic preconditioning was used, wherein exposure to sublethal hypoxia (8% oxygen) for 3 hours renders postnatal day (PND) 6 animals completely resistant to a cerebral hypoxic-ischemic insult imposed 24 hours later. Postnatal day 6 animals were treated 0.5 hour before preconditioning hypoxia with the nonselective NOS inhibitor L-nitroarginine (2 mg/kg intraperitoneally). This treatment, which resulted in a 67 to 81% inhibition of calcium-dependent constitutive NOS activity 0.5 to 3.5 hours after its administration, completely blocked preconditioning-induced protection. However, administration of the neuronal NOS inhibitor 7-nitroindazole (40 mg/kg intraperitoneally) before preconditioning hypoxia, which decreased constitutive brain NOS activity by 58 to 81%, was without effect on preconditioning-induced cerebroprotection, as was pretreatment with the inducible NOS inhibitor aminoguanidine (400 mg/kg intraperitoneally). The protective effects of preconditioning were also not blocked by treating animals with competitive [3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate; 5 mg/kg intraperitoneally] or noncompetitive (MK-801; 1 mg/kg intraperitoneally) N-methyl-D-aspartate receptor antagonists prior to preconditioning hypoxia. These findings indicate that NO production and activity are critical to the induction of ischemic tolerance in this model. However, the results argue against the involvement of the neuronal NOS isoform, activated secondary to a hypoxia-induced stimulation of N-methyl-D-aspartate receptors, and against the involvement of the inducible NOS isoform, but rather suggest that NO produced by the endothelial NOS isoform is required to mediate this profound protective effect.
doi_str_mv 10.1097/00004647-199903000-00011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69623886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1097_00004647-199903000-00011</sage_id><sourcerecordid>69623886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c531t-a72c587a5924b2cdafc370518049f0ec8a06eb8f538f7088df550d215d7c32983</originalsourceid><addsrcrecordid>eNqF0F1LQyEYwHGJoq2XrxBeRHen9Jx51MsYvUFtEQu6E6ePy3F2XHoG9e1zbb3cJYgIP33gjxCm5JwSyS9IXoN6wAsqpSRVvhV5U7qD-pQxWXBC613UJyWnRc3FSw8dpDTPRFSM7aMeJYQLIVgf2ZHvojd4_O4t4AewXneQ8BAiTKNu8F0yr7DIYBIaiLo1gH2LNR5BaHWXwZPu8EOw0ODg8O3HMrxn_BjBhNb6zofWt7MjtOd0k-B4ex6i5-uryfC2uB_f3A0v7wvDKtoVmpeGCa6ZLAfT0ljtTMUJo4IMpCNghCY1TIVjlXCcCGEdY8SWlFluqlKK6hCdbf5dxvC2gtSphU8Gmka3EFZJ1bIuKyHqDMUGmhhSiuDUMvqFjh-KErUurL4Lq5_C6qtwfnqynbGaLsD-ebhJmsHpFuhkdOPW0Xz6dXztSGZsw5KegZqHVWxzmv_nfwI5W5HE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69623886</pqid></control><display><type>article</type><title>Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Gidday, Jeffrey M. ; Shah, Aarti R. ; Maceren, Raymond G. ; Wang, Qiong ; Pelligrino, Dale A. ; Holtzman, David M. ; Park, T. S.</creator><creatorcontrib>Gidday, Jeffrey M. ; Shah, Aarti R. ; Maceren, Raymond G. ; Wang, Qiong ; Pelligrino, Dale A. ; Holtzman, David M. ; Park, T. S.</creatorcontrib><description>Neuroprotection against cerebral ischemia can be realized if the brain is preconditioned by previous exposure to a brief period of sublethal ischemia. The present study was undertaken to test the hypothesis that nitric oxide (NO) produced from the neuronal isoform of NO synthase (NOS) serves as a necessary signal for establishing an ischemia-tolerant state in brain. A newborn rat model of hypoxic preconditioning was used, wherein exposure to sublethal hypoxia (8% oxygen) for 3 hours renders postnatal day (PND) 6 animals completely resistant to a cerebral hypoxic-ischemic insult imposed 24 hours later. Postnatal day 6 animals were treated 0.5 hour before preconditioning hypoxia with the nonselective NOS inhibitor L-nitroarginine (2 mg/kg intraperitoneally). This treatment, which resulted in a 67 to 81% inhibition of calcium-dependent constitutive NOS activity 0.5 to 3.5 hours after its administration, completely blocked preconditioning-induced protection. However, administration of the neuronal NOS inhibitor 7-nitroindazole (40 mg/kg intraperitoneally) before preconditioning hypoxia, which decreased constitutive brain NOS activity by 58 to 81%, was without effect on preconditioning-induced cerebroprotection, as was pretreatment with the inducible NOS inhibitor aminoguanidine (400 mg/kg intraperitoneally). The protective effects of preconditioning were also not blocked by treating animals with competitive [3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate; 5 mg/kg intraperitoneally] or noncompetitive (MK-801; 1 mg/kg intraperitoneally) N-methyl-D-aspartate receptor antagonists prior to preconditioning hypoxia. These findings indicate that NO production and activity are critical to the induction of ischemic tolerance in this model. However, the results argue against the involvement of the neuronal NOS isoform, activated secondary to a hypoxia-induced stimulation of N-methyl-D-aspartate receptors, and against the involvement of the inducible NOS isoform, but rather suggest that NO produced by the endothelial NOS isoform is required to mediate this profound protective effect.</description><identifier>ISSN: 0271-678X</identifier><identifier>EISSN: 1559-7016</identifier><identifier>DOI: 10.1097/00004647-199903000-00011</identifier><identifier>PMID: 10078885</identifier><identifier>CODEN: JCBMDN</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animals ; Animals, Newborn ; Biological and medical sciences ; Brain Ischemia - prevention &amp; control ; Calcium - pharmacology ; Dizocilpine Maleate - pharmacology ; Enzyme Inhibitors - pharmacology ; Guanidines - pharmacology ; Hypoxia - physiopathology ; Indazoles - pharmacology ; Medical sciences ; Neuropharmacology ; Neuroprotective agent ; Nitric Oxide - physiology ; Nitric Oxide Synthase - antagonists &amp; inhibitors ; Nitric Oxide Synthase - physiology ; Nitric Oxide Synthase Type II ; Nitric Oxide Synthase Type III ; Nitroarginine - pharmacology ; Oxygen - administration &amp; dosage ; Pharmacology. Drug treatments ; Piperazines - pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, N-Methyl-D-Aspartate - antagonists &amp; inhibitors ; Receptors, N-Methyl-D-Aspartate - physiology</subject><ispartof>Journal of cerebral blood flow and metabolism, 1999-03, Vol.19 (3), p.331-340</ispartof><rights>1999 The International Society for Cerebral Blood Flow and Metabolism</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c531t-a72c587a5924b2cdafc370518049f0ec8a06eb8f538f7088df550d215d7c32983</citedby><cites>FETCH-LOGICAL-c531t-a72c587a5924b2cdafc370518049f0ec8a06eb8f538f7088df550d215d7c32983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1097/00004647-199903000-00011$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1097/00004647-199903000-00011$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21799,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1707880$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10078885$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gidday, Jeffrey M.</creatorcontrib><creatorcontrib>Shah, Aarti R.</creatorcontrib><creatorcontrib>Maceren, Raymond G.</creatorcontrib><creatorcontrib>Wang, Qiong</creatorcontrib><creatorcontrib>Pelligrino, Dale A.</creatorcontrib><creatorcontrib>Holtzman, David M.</creatorcontrib><creatorcontrib>Park, T. S.</creatorcontrib><title>Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning</title><title>Journal of cerebral blood flow and metabolism</title><addtitle>J Cereb Blood Flow Metab</addtitle><description>Neuroprotection against cerebral ischemia can be realized if the brain is preconditioned by previous exposure to a brief period of sublethal ischemia. The present study was undertaken to test the hypothesis that nitric oxide (NO) produced from the neuronal isoform of NO synthase (NOS) serves as a necessary signal for establishing an ischemia-tolerant state in brain. A newborn rat model of hypoxic preconditioning was used, wherein exposure to sublethal hypoxia (8% oxygen) for 3 hours renders postnatal day (PND) 6 animals completely resistant to a cerebral hypoxic-ischemic insult imposed 24 hours later. Postnatal day 6 animals were treated 0.5 hour before preconditioning hypoxia with the nonselective NOS inhibitor L-nitroarginine (2 mg/kg intraperitoneally). This treatment, which resulted in a 67 to 81% inhibition of calcium-dependent constitutive NOS activity 0.5 to 3.5 hours after its administration, completely blocked preconditioning-induced protection. However, administration of the neuronal NOS inhibitor 7-nitroindazole (40 mg/kg intraperitoneally) before preconditioning hypoxia, which decreased constitutive brain NOS activity by 58 to 81%, was without effect on preconditioning-induced cerebroprotection, as was pretreatment with the inducible NOS inhibitor aminoguanidine (400 mg/kg intraperitoneally). The protective effects of preconditioning were also not blocked by treating animals with competitive [3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate; 5 mg/kg intraperitoneally] or noncompetitive (MK-801; 1 mg/kg intraperitoneally) N-methyl-D-aspartate receptor antagonists prior to preconditioning hypoxia. These findings indicate that NO production and activity are critical to the induction of ischemic tolerance in this model. However, the results argue against the involvement of the neuronal NOS isoform, activated secondary to a hypoxia-induced stimulation of N-methyl-D-aspartate receptors, and against the involvement of the inducible NOS isoform, but rather suggest that NO produced by the endothelial NOS isoform is required to mediate this profound protective effect.</description><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Biological and medical sciences</subject><subject>Brain Ischemia - prevention &amp; control</subject><subject>Calcium - pharmacology</subject><subject>Dizocilpine Maleate - pharmacology</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Guanidines - pharmacology</subject><subject>Hypoxia - physiopathology</subject><subject>Indazoles - pharmacology</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neuroprotective agent</subject><subject>Nitric Oxide - physiology</subject><subject>Nitric Oxide Synthase - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase - physiology</subject><subject>Nitric Oxide Synthase Type II</subject><subject>Nitric Oxide Synthase Type III</subject><subject>Nitroarginine - pharmacology</subject><subject>Oxygen - administration &amp; dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, N-Methyl-D-Aspartate - antagonists &amp; inhibitors</subject><subject>Receptors, N-Methyl-D-Aspartate - physiology</subject><issn>0271-678X</issn><issn>1559-7016</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0F1LQyEYwHGJoq2XrxBeRHen9Jx51MsYvUFtEQu6E6ePy3F2XHoG9e1zbb3cJYgIP33gjxCm5JwSyS9IXoN6wAsqpSRVvhV5U7qD-pQxWXBC613UJyWnRc3FSw8dpDTPRFSM7aMeJYQLIVgf2ZHvojd4_O4t4AewXneQ8BAiTKNu8F0yr7DIYBIaiLo1gH2LNR5BaHWXwZPu8EOw0ODg8O3HMrxn_BjBhNb6zofWt7MjtOd0k-B4ex6i5-uryfC2uB_f3A0v7wvDKtoVmpeGCa6ZLAfT0ljtTMUJo4IMpCNghCY1TIVjlXCcCGEdY8SWlFluqlKK6hCdbf5dxvC2gtSphU8Gmka3EFZJ1bIuKyHqDMUGmhhSiuDUMvqFjh-KErUurL4Lq5_C6qtwfnqynbGaLsD-ebhJmsHpFuhkdOPW0Xz6dXztSGZsw5KegZqHVWxzmv_nfwI5W5HE</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>Gidday, Jeffrey M.</creator><creator>Shah, Aarti R.</creator><creator>Maceren, Raymond G.</creator><creator>Wang, Qiong</creator><creator>Pelligrino, Dale A.</creator><creator>Holtzman, David M.</creator><creator>Park, T. S.</creator><general>SAGE Publications</general><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990301</creationdate><title>Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning</title><author>Gidday, Jeffrey M. ; Shah, Aarti R. ; Maceren, Raymond G. ; Wang, Qiong ; Pelligrino, Dale A. ; Holtzman, David M. ; Park, T. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c531t-a72c587a5924b2cdafc370518049f0ec8a06eb8f538f7088df550d215d7c32983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Biological and medical sciences</topic><topic>Brain Ischemia - prevention &amp; control</topic><topic>Calcium - pharmacology</topic><topic>Dizocilpine Maleate - pharmacology</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Guanidines - pharmacology</topic><topic>Hypoxia - physiopathology</topic><topic>Indazoles - pharmacology</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neuroprotective agent</topic><topic>Nitric Oxide - physiology</topic><topic>Nitric Oxide Synthase - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase - physiology</topic><topic>Nitric Oxide Synthase Type II</topic><topic>Nitric Oxide Synthase Type III</topic><topic>Nitroarginine - pharmacology</topic><topic>Oxygen - administration &amp; dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, N-Methyl-D-Aspartate - antagonists &amp; inhibitors</topic><topic>Receptors, N-Methyl-D-Aspartate - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gidday, Jeffrey M.</creatorcontrib><creatorcontrib>Shah, Aarti R.</creatorcontrib><creatorcontrib>Maceren, Raymond G.</creatorcontrib><creatorcontrib>Wang, Qiong</creatorcontrib><creatorcontrib>Pelligrino, Dale A.</creatorcontrib><creatorcontrib>Holtzman, David M.</creatorcontrib><creatorcontrib>Park, T. S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cerebral blood flow and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gidday, Jeffrey M.</au><au>Shah, Aarti R.</au><au>Maceren, Raymond G.</au><au>Wang, Qiong</au><au>Pelligrino, Dale A.</au><au>Holtzman, David M.</au><au>Park, T. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning</atitle><jtitle>Journal of cerebral blood flow and metabolism</jtitle><addtitle>J Cereb Blood Flow Metab</addtitle><date>1999-03-01</date><risdate>1999</risdate><volume>19</volume><issue>3</issue><spage>331</spage><epage>340</epage><pages>331-340</pages><issn>0271-678X</issn><eissn>1559-7016</eissn><coden>JCBMDN</coden><abstract>Neuroprotection against cerebral ischemia can be realized if the brain is preconditioned by previous exposure to a brief period of sublethal ischemia. The present study was undertaken to test the hypothesis that nitric oxide (NO) produced from the neuronal isoform of NO synthase (NOS) serves as a necessary signal for establishing an ischemia-tolerant state in brain. A newborn rat model of hypoxic preconditioning was used, wherein exposure to sublethal hypoxia (8% oxygen) for 3 hours renders postnatal day (PND) 6 animals completely resistant to a cerebral hypoxic-ischemic insult imposed 24 hours later. Postnatal day 6 animals were treated 0.5 hour before preconditioning hypoxia with the nonselective NOS inhibitor L-nitroarginine (2 mg/kg intraperitoneally). This treatment, which resulted in a 67 to 81% inhibition of calcium-dependent constitutive NOS activity 0.5 to 3.5 hours after its administration, completely blocked preconditioning-induced protection. However, administration of the neuronal NOS inhibitor 7-nitroindazole (40 mg/kg intraperitoneally) before preconditioning hypoxia, which decreased constitutive brain NOS activity by 58 to 81%, was without effect on preconditioning-induced cerebroprotection, as was pretreatment with the inducible NOS inhibitor aminoguanidine (400 mg/kg intraperitoneally). The protective effects of preconditioning were also not blocked by treating animals with competitive [3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate; 5 mg/kg intraperitoneally] or noncompetitive (MK-801; 1 mg/kg intraperitoneally) N-methyl-D-aspartate receptor antagonists prior to preconditioning hypoxia. These findings indicate that NO production and activity are critical to the induction of ischemic tolerance in this model. However, the results argue against the involvement of the neuronal NOS isoform, activated secondary to a hypoxia-induced stimulation of N-methyl-D-aspartate receptors, and against the involvement of the inducible NOS isoform, but rather suggest that NO produced by the endothelial NOS isoform is required to mediate this profound protective effect.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>10078885</pmid><doi>10.1097/00004647-199903000-00011</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0271-678X
ispartof Journal of cerebral blood flow and metabolism, 1999-03, Vol.19 (3), p.331-340
issn 0271-678X
1559-7016
language eng
recordid cdi_proquest_miscellaneous_69623886
source MEDLINE; SAGE Complete
subjects Animals
Animals, Newborn
Biological and medical sciences
Brain Ischemia - prevention & control
Calcium - pharmacology
Dizocilpine Maleate - pharmacology
Enzyme Inhibitors - pharmacology
Guanidines - pharmacology
Hypoxia - physiopathology
Indazoles - pharmacology
Medical sciences
Neuropharmacology
Neuroprotective agent
Nitric Oxide - physiology
Nitric Oxide Synthase - antagonists & inhibitors
Nitric Oxide Synthase - physiology
Nitric Oxide Synthase Type II
Nitric Oxide Synthase Type III
Nitroarginine - pharmacology
Oxygen - administration & dosage
Pharmacology. Drug treatments
Piperazines - pharmacology
Rats
Rats, Sprague-Dawley
Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors
Receptors, N-Methyl-D-Aspartate - physiology
title Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T08%3A23%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nitric%20Oxide%20Mediates%20Cerebral%20Ischemic%20Tolerance%20in%20a%20Neonatal%20Rat%20Model%20of%20Hypoxic%20Preconditioning&rft.jtitle=Journal%20of%20cerebral%20blood%20flow%20and%20metabolism&rft.au=Gidday,%20Jeffrey%20M.&rft.date=1999-03-01&rft.volume=19&rft.issue=3&rft.spage=331&rft.epage=340&rft.pages=331-340&rft.issn=0271-678X&rft.eissn=1559-7016&rft.coden=JCBMDN&rft_id=info:doi/10.1097/00004647-199903000-00011&rft_dat=%3Cproquest_cross%3E69623886%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69623886&rft_id=info:pmid/10078885&rft_sage_id=10.1097_00004647-199903000-00011&rfr_iscdi=true